Stealth BioTherapeutics

Stealth BioTherapeutics Employees

10 people indexed:

Anthony Abbruscato

Vice President, Clinical Development

zi6957w.q5ix48qpfi@v7i52i52q.z6x Sign up to see email

6ff2kq1.wv8jxd75j0@4i2d593xw.d0k Sign up to see email
Brian Blakey

Chief Business Officer

5vfxz.420w51@8342vz4j5.vd0 Sign up to see email

vz628.20f3v6@z437uuwg7.f30 Sign up to see email
Brian Saxton

Vice President, Quality Assurance

5782w.2352d4@u8dwpk6p7.3f9 Sign up to see email

2j2k0.148jk1@zw9wgwp90.j10 Sign up to see email
David A. Brown

Senior Vice President, Discovery

4305f.j.3803f@8849gu9q2.pkp Sign up to see email

x5jfg.x.gz053@f1039k266.548 Sign up to see email
Henry Hess

Chief Legal Counsel

vj0i8.q1g3@fk3zdqw4q.gp2 Sign up to see email

vqpfi.u69x@k484d1gk2.g5i Sign up to see email
Jim Carr

Chief Clinical Development Officer

1n7.v80y@qux8n9pgw.w3q Sign up to see email

1zn.nq56@v9f1nq4xz.u92 Sign up to see email
Mike Malynn

Chief People Officer

u383.pwvw7u@27gv37rg3.r9f Sign up to see email

v1qj.pw12vd@41gujprj5.1f2 Sign up to see email
Naidong Ye

Senior Vice President, Pharmaceutical Sciences and Technical Operations

qk4fu18.zu@xz3jk2x22.8r3 Sign up to see email

k7q34w7.pv@7qvw195r3.8v8 Sign up to see email
Reenie McCarthy

Chief Executive Officer

zffxx5.zpkzvwkx@vfkkxkvx2.61f Sign up to see email

p666dw.984dg4f7@zwx2gxpx1.gxz Sign up to see email
Rekha Sathyanarayana

Senior Vice President, Clinical Operations

1v8f5.g8g150vgq95ix4@xp5u07vv8.u8z Sign up to see email

jf9f0.v3wj3u0q6jfx28@g2w3944z2.zj5 Sign up to see email

Stealth BioTherapeutics Company Information

Stealth BioTherapeutics, located at 123 Highland Ave, Suite 201, Needham, MA 02494, develops therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. The company is investigating elamipretide in late-stage clinical studies for ophthalmic diseases, rare neuromuscular disorders, and rare cardiomyopathies. Additionally, Stealth BioTherapeutics is evaluating a second-generation clinical-stage candidate, SBT-272, for rare neurological disease indications such as amyotrophic lateral sclerosis. The company offers an Expanded Access Program for investigational drugs to patients with serious or life-threatening conditions who are ineligible for clinical trials. Stealth BioTherapeutics also supports educational programs and initiatives that provide healthcare providers and patient communities with information on disease awareness and therapeutic management.

Report inaccurate information